Merck for Mothers’ approach to helping to reduce maternal
mortality through investments to address the #1 driver of maternal
deaths - postpartum hemorrhage
Merck for Mothers
1
is committed to supporting efforts to reduce maternal mortality
globally. We collaborate across sectors — working with NGOs,
professional associations, entrepreneurs, UN agencies, research
institutions, governments and other companies – to address leading
causes of maternal mortality and support countries in their
efforts to strengthen health systems.
Our collaborative approach is undertaken with the goal of
improving access to quality maternal health care, including access
to quality medicines, and has been informed by consensus
recommendations from the United Nations Commission on Life Saving
Commodities for Women and Children
2
.
As the number one driver of maternal mortality, especially in low-
and middle-income countries, Merck for Mothers has taken a
comprehensive approach to addressing postpartum hemorrhage, or
excessive bleeding after childbirth. Our efforts to address
postpartum hemorrhage are informed by a health system
strengthening approach and identifying possible solutions to
challenges through
human centered design
3,4,5,6
. Our aim is to identify, support and advance evidence-based
practices for effectively, safely and sustainably introducing new
solutions as part of routine standard of care and in accordance
with guidelines.
We have invested in new innovations
7
and research including clinical trials
8,9,10
, studies to assess the quality of medicines
11
, research on uterotonic use at country level
12
and the translation of normative recommendations into policy
13
and practice in support of safe and appropriate adoption of
solutions to prevent postpartum hemorrhage into health care
delivery systems. Our collaborations have focused on:
-
Supporting the translation of normative guidelines into policy
14,15,16,17
and practice at a national level through the development of
comprehensive resources, educational tools and job aids
18
-
Training and mentorship for health care workers and procurement
managers to support safe and appropriate uterotonic use and
improvements in supply chains
19
-
Assistance in exploring innovative financing for new maternal
health medicines
20
-
Promoting respectful care through amplifying women’s voices
21
and supporting their choices through health literacy
22
Health inequities are often exacerbated by the inability to access
quality-assured medicines. Merck for Mothers is investing in
country-level implementation research and supporting processes to
build capacity of local institutions to introduce innovations
23,24
and enhance decision making around the use of new medicines,
including cost-effectiveness studies, and exploring the challenges
and potential solutions to support safe introduction.
At a global level, we prioritize shared learning, supporting
global conferences and workshops and disseminating evidence on the
experiences of our collaborators - most recently through our
support of a supplement in
International Journal of Gynecology & Obstetrics
on postpartum hemorrhage prevention and management
25
.
These investments in addressing postpartum hemorrhage are a key
part of Merck for Mothers broader strategy to improve the quality
of maternal health care
26
.
1
Merck for Mothers, known as MSD for Mothers outside the
United States and Canada, is an initiative of Merck & Co.,
Inc., Rahway, NJ, U.S.A.
2
UN Commission on Life-Saving Commodities for Women and
Children
3
Smiles for Mothers Program is using Human
Centered-Design to co-create Public Health Innovations
4
Human-centered Design for Life: How Smiles for Mothers
is Keeping Mothers Alive
5
Human Centered Design: PPH Reduction Initiative in
Nigeria
6
Co-creating an improved response to postpartum
hemorrhage
7
Profile of the Jada
®
System: the vacuum-induced hemorrhage control device for
treating abnormal postpartum uterine bleeding and
postpartum hemorrhage
8
Heat-Stable Carbetocin versus Oxytocin to Prevent
Hemorrhage after Vaginal Birth
9
Duration of third stage labour and postpartum blood
loss: a secondary analysis of the WHO CHAMPION trial
data
10
The 'Birth day' prize, European Commission
11
Oxytocin Quality –Evidence for Action
12
A descriptive study of healthcare-providers’ experiences
with the use and quality of oxytocin for the prevention
of post-partum hemorrhage in Nigeria: A nation-wide
survey
13
FIGO Generic Postpartum Haemorrhage Protocol and Care
Pathways
14
Niger State updated their Essential Medicines List after
a 3-day workshop
15
Kano State has validated their Essential Medicines List
16
National Guidelines on Quality Obstetrics and Perinatal
Care, Ministry of Health in Kenya
17
Essential Maternal and Newborn Clinical Care Guidelines
for Uganda, May 2022
18
An Opportunity to reduce Maternal Mortality in Nigeria
19
Federal Ministry of Health reviews Life Saving Skills
Manuals with Stakeholders
20
Opportunities to reduce PPH: Making financing for the
procurement of maternal health commodities sustainable
21
Another Listen, What Women Want- White Ribbon Alliance
(page 43)
22
Raising community awareness for maternal health through
Patient Literacy Materials
23
FIGO- Improving access to essential medicines to reduce
postpartum haemorrhage (PPH) morbidity and mortality
(IAP)
24
Merck for Mothers website- map of grantees and
collaborators; select Global to find Concept Foundation;
select Kenya to find Jhpiego
25
Improving access to essential medicines to reduce
postpartum hemorrhage morbidity and mortality
26
Merck for Mothers website
Who We Are
What We Do
Where We Work
Learn More
Connect
Contact
Terms of Use
Privacy Policy